医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories Announces the Launch of Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. Market

2018年03月16日 PM04:42
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal® Allergy 24HR Tablets in the United States market as approved by the U.S. Food and Drug Administration (USFDA).

Levocetirizine Dihydrochloride Tablets USP, 5 mg is an over-the-counter antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing.

“This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,” says Milan Kalawadia, Vice President and Head, US Over-the-Counter and Speciality Rx businesses, Dr. Reddy’s Laboratories. “We look forward to collaborating with our customers to bring high-quality, affordable store brand alternatives to the market.”

The Xyzal® Allergy 24HR Tablets brand had U.S. sales of approximately $71 million for the most recent twelve months ending in January 2018 according to IRI*.

Dr. Reddy’s Levocetirizine Dihydrochloride Tablets USP is available in 5 mg strength and in various consumer oriented package sizes.

Xyzal® is a registered trademark of UCB group of companies.

*IRI Latest 52 wks. period ending January 28, 2018
OTC-001-0318

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein

View source version on businesswire.com: http://www.businesswire.com/news/home/20180316005204/en/

CONTACT

INVESTOR RELATIONS
SAUNAK SAVLA, +91-40-49002135
saunaks@drreddys.com
or
MEDIA
RELATIONS
CALVIN PRINTER, +91-40- 49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc